MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/pharmaceutics17101323

Медицинская библиотека · Pharmaceutics · 2025

Phase I Clinical Study with the GRPR-Antagonist [99mTc]Tc-DB8 for SPECT Imaging of Prostate Cancer: Does the Injected Peptide Mass Make a Difference?

Orlova Anna, Rybina Anastasia, Medvedeva Anna, Zelchan Roman, Bragina Olga, Tashireva Liubov, Larkina Maria, Varvashenya Ruslan, Lushnikova Nadejda, Kanellopoulos Panagiotis, Maina Theodosia, Nock Berthold A, Tolmachev Vladimir, Chernov Vladimir

СтатьяПеревод пока не подготовлен

Аннотация

Background/

Objectives

The gastrin-releasing peptide receptor (GRPR) shows high-density expression in prostate cancer (PCa), especially in the early stages of the disease. The introduction of a safe radiotracer for assessing GRPR-expression in PCa may serve as an alternative or complementary tracer to PSMA-directed probes for patients with insufficient PSMA expression. In the present study, the tolerability and safety, biodistribution, and dosimetry of the new GRPR-targeting radiopeptide [99mTc]Tc-DB8 were investigated for the first time in male PCa patients. A mass escalation study was performed, aiming to improve tumor-to-background contrast and, thereby, to enhance diagnostic accuracy.

Methods

Sixteen male patients were enrolled in a single-center diagnostic open-label exploratory Phase I clinical trial. Patients were administered a single intravenous injection of 40, 80, or 120 µg of [99mTc]Tc-DB8 peptide (n = 5-6) and underwent whole-body planar imaging (anterior and posterior) 2, 4, 6, and 24 h post-injection (pi) and SPECT-CT acquisition 2, 4, and 6 h pi.

Results

Administration of [99mTc]Tc-DB8 was well tolerated at all tested peptide masses. The effective dose did not differ significantly between the injected peptide mass and was 0.005 ± 0.003 mSv/MBq. High activity uptake was observed in the pancreas and kidneys, which 3-fold decreased with an increasing injected peptide mass from 40 to 120 µg. The activity uptake in primary tumors did not differ significantly between cohorts injected with different peptide masses [SUVmax 1.65-9.96]. The tumor-to-muscle ratios increased with time and were the highest for the cohort injected with 120 µg of peptide, 7.2 ± 3.1 (4.64-11-25) at 4 h pi.

Conclusions

Single intravenous administration of [99mTc]Tc-DB8, for visualization of GRPR expression in PCa using SPECT imaging was well tolerated in a peptide mass range of 40-120 µg. An injected peptide mass of 80-120 µg/patient and SPECT acquisition 2-4 h pi were found to be optimal for further clinical studies due to the significantly lower activity accumulation in the pancreas and kidneys.

Для цитирования: Orlova Anna, Rybina Anastasia, Medvedeva Anna, Zelchan Roman, Bragina Olga, Tashireva Liubov, Larkina Maria, Varvashenya Ruslan, Lushnikova Nadejda, Kanellopoulos Panagiotis, Maina Theodosia, Nock Berthold A, Tolmachev Vladimir, Chernov Vladimir. Phase I Clinical Study with the GRPR-Antagonist [99mTc]Tc-DB8 for SPECT Imaging of Prostate Cancer: Does the Injected Peptide Mass Make a Difference?. Pharmaceutics. 2025. DOI: 10.3390/pharmaceutics17101323.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.